By Peter A. McCullough, MD, MPH
As Elon Musk and DOGE take a chainsaw to the bloated US government bureaucracy, it there appears to be one slush fund after another with no accountability and without tangible benefit to Americans. Listen to this brief update on the Advanced Research Projects Agency for Health (ARPA-H) which is a research funding agency that purportedly supports transformative biomedical and health breakthroughs – ranging from the molecular to the societal – to provide health solutions for all.
Senator Joni Ernst wrote Robert F. Kennedy a concerning letter about one ARPA-H check for $28 M to Vaccine Company, Inc, operating out of a PO Box in Maryland. Ernst’s cursory investigation revealed Vaccine Company, Inc, is brand new, has no physical plant or address, and yet received a generous $24M payment from ARPA-H. Ernst points out that ARPA-H received an additional $1.5B from the Biden administration in 2022.
The Vaccines Company, Inc, does not have a website but government sources confirm they received $24M in 2024. Senator Ernst is correct, they are running the company out of this post office box in Bethesda, MD.
To be fair, the Vaccines Company has a COVID-19 candidate VXCO-100 reporting they had completed a clinical trial of VXCO-1 (3 dose levels at 1 and 6 months) versus a mRNA vaccine 2 does 21 days apart in normal healthy volunteers free of SARS-CoV-2 infection for six months. Pregnant women were excluded. Their two clinical trial locations were: Perinatal HIV Research Unit (PHRU), Chris Hani Baragwanath Academic Hospital, and the HIV and other Infectious Diseases Research Unit (HIDRU), South African Medical Research Council. Manuscripts on the description of VXCO-100 and its trial results are forthcoming. I find it odd the company does not have a website and third party searches have to be done to find its product. Many readers will wonder is this worth investing our tax dollars with no NIH oversight?
According to statements from former HHS Secretary Xavier Becerra, ARPA-H, while housed within the NIH, is not be subject to direct NIH oversight, meaning it will operate with its own independent policies and processes, reporting directly to the HHS Secretary instead of the NIH Director; essentially, Becerra has established ARPA-H as a distinct entity within NIH with autonomy from standard NIH procedures.
I think it’s time for DOGE to take a look at ARPA-H and its network that has no labs or intramural programs or NIH oversight. Liz MacDonald claims has been allocated a stunning $4B taxpayer dollars! Please be sure to follow the Evening Edit on X @EveningEdit.
Please subscribe to FOCAL POINTS as a paying ($5 monthly) or founder member so we can continue to bring you the truth.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
www.mcculloughfnd.org
Share this post